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Abstract
Purpose Recent studies in patients with inflammatory bow-
el diseases (IBD) on thiopurine therapy suggest that too low
6-thioguanine nucleotide concentrations (6-TGN) and too
high methylmercaptopurine nucleotide concentrations
(MMPN) can be reversed by a combination therapy of
allopurinol and low-dose thiopurines. To date, however,
optimal dosing has not been established. The aim of this
study was to evaluate the minimal allopurinol doses neces-
sary to achieve adequate 6-TGN concentrations in combi-
nation with low-dose azathioprine.
Methods A stepwise dose-escalation of allopurinol was
performed in 11 azathioprine-pretreated IBD patients
with inadequately low 6-TGN concentrations (<235
pmol/8×108 erythrocytes) and/or elevated MMPN con-
centrations (>5,000 pmol/8×108 erythrocytes) and/or el-
evated liver enzymes (alanine aminotransferase and/or
aspartate aminotransferase levels one- to threefold the
upper limit of normal). Six patients were recruited into
an open study, and five were treated in the context of
an individualized therapeutic approach. Adverse effects,
azathioprine metabolites, liver enzymes and whole blood
counts were monitored two to three times per month.
Results Adequate 6-TGN concentrations were achieved
with a combination of 25 mg allopurinol and 50 mg azathi-
oprine in one patient and with 50 mg allopurinol and 50 mg
azathioprine in nine patients. Median 6-TGN concentrations
(range) were 336 (290–488) pmol/8×108 erythrocytes after
an 8-week-long intake of the final dose combination. One
patient dropped out due to nausea after the first intake.
MMPN concentrations and liver enzymes normalized im-
mediately in all affected patients. All patients finishing the
dose-escalation regimen tolerated the treatment without
toxicity.
Conclusions Combination therapy with only 50 mg allopu-
rinol and 50 mg azathioprine daily is sufficient, efficacious
and safe in most IBD patients with inadequate thiopurine
metabolite concentrations to optimize azathioprine-based
IBD therapy.
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Introduction
In patients with inflammatory bowel disease (IBD), the
thiopurine immunomodulators azathioprine and 6-
mercaptopurine are used to induce and maintain remission.
These substances are prodrugs that undergo a complex meta-
bolic transformation resulting in the formation of the pharma-
cologically active, immunosuppressive metabolites 6-
thioguanine nucleotides (6-TGN) [1]. In a competing path-
way, the formation of methyl-thiopurines, such as the
methylmercaptopurine ribonucleotides (6-MMPN), which
are not directly immunosuppressive, is catalyzed by the en-
zyme thiopurine methyl transferase (TPMT). Between 10 and
15 % of IBD patients are thiopurine refractory due to the
preferential production of 6-MMPN rather than active 6-
TGN [1–4]. This may result in insufficient clinical response
and/or an increased rate of adverse effects [2, 5]. Upon dose-
escalation in these patients, concentrations of 6-TGN often
remain below the lower limit of the therapeutic range of
approximately 235 pmol/8×108 erythrocytes (EC) [2] while
conversely 6-MMPN concentrations increase above a value of
5,000 pmol/8×108 EC, which has been associated with an
increased risk for hepatotoxicity [1]. Several studies have
recently provided evidence that IBD patients with an unfavor-
able MMPN/6-TGN ratio can benefit from adding allopurinol
to a reduced dose of thiopurines. The effects of this combina-
tion therapy are (1) an increased production of 6-TGN, (2) a
reduced formation of 6-MMPN, (3) a normalization of
liver function tests and (4) better disease control and less
corticosteroid usage [6–12]. In terms of the metabolic
pathway of thiopurines, the shunting of metabolism to-
wards the production of 6-TGN induced by allopurinol
can be explained by inhibition of the enzyme xanthine
oxidase. However, the mechanism by which allopurinol
leads to a reduction in 6-MMPN concentrations has not
yet been determined.
In previous studies and case reports, thiopurine doses
were reduced to 25–50 % of the initial thiopurine dose and
usually combined with daily doses of allopurinol 100–
200 mg [6–9, 12–15] or even 300 mg [10]. The thiopurine
dose was reduced empirically or according to published
recommendations. Accordingly, in their study, Ansari et al.
[9] reduced the thiopurine dose to 25–33 % of the
monotherapy dose as proposed earlier for the use of
thiopurine in renal transplant patients [16]. Other re-
searchers [15] reduced the thiopurine dose to 25 % of the
standard dose based on the report by Sparrow et al. [6].
However, the rationale for the selection of daily doses of
100–200 mg allopurinol has never been provided; this is
particularly true in the case of the combination therapy in
renal transplant recipients, where only 25 mg allopurinol
each second day was administered [16]. To our knowledge,
the optimal allopurinol–azathioprine combination dose has
not been studied systematically in IBD patients, and neither
the minimally effective nor the maximally tolerated doses of
this combination are as yet known. The appropriate dose
adjustment with a decrease of both azathioprine and allopu-
rinol drug exposures to a minimum may help to avoid toxic
side effects. Accordingly, we conducted a dose-escalation
study to evaluate the minimal allopurinol dose that, in
combination with low-dose azathioprine, would result in
therapeutic 6-TGN concentrations in azathioprine-
pretreated patients. Our secondary objectives were to eval-
uate whether maintenance of remission could be achieved
with the low dose allopurinol–azathioprine combination and
whether allopurinol influences TPMT activity.
Materials and methods
Study procedures
We conducted a prospective, open, non-randomized single-
center cohort study in patients with IBD. Six otherwise
healthy female azathioprine-pretreated patients with Crohn’s
disease (CD) and ulcerative colitis (UC) who had received
subtherapeutic 6-TGN concentrations (<235 pmol/8×108
EC) and insufficient disease control despite adequate thera-
py dosing and duration, and/or had elevated 6-MMPN con-
centrations (>5,000 pmol/8×108 EC) and/or elevated liver
enzymes [alanine aminotransferase (ALT) and/or aspartate
aminotransferase (AST) of one- to threefold the upper limit
of normal range (ULN)] were included in the study. Addi-
tionally, we performed a stepwise dose-escalation of allopu-
rinol in five male and female CD and UC patients who did
not meet the study eligibility criteria (e.g. patients with
relevant comorbidities or obesity), but who we considered
would benefit clinically from the combination therapy of
allopurinol and low-dose azathioprine. These patients were
treated with allopurinol in combination with azathio-
prine in the context of an individualized therapeutic
approach.
The inclusion criteria were: age ≥18 years, normal weight
with a body mass index (BMI) of 18–30 kg/m2, a confirmed
diagnosis of either CD or UC based on clinical, endoscopic
and histologic criteria, normal TPMT activity (≥30 nmol
MTG/gHb/h), azathioprine metabolite concentrations and/or
hepatic azathioprine side effects as defined above. The main
exclusion criteria were pregnancy or lactation, any current
or previous immunosuppressive therapy except for cortico-
steroids and/or azathioprine within 3 months before the first
study-drug intake and any clinically relevant comorbidity
(including malignancy and relevant infections in the last
3 months), as based on extensive medical history, physical
examination, vital signs, routine laboratory screen and 12-
lead electrocardiogram (ECG).
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On day 1 of the study, the azathioprine dose was reduced to
a dose of 50 mg once daily (qd) for one 28-day therapy cycle.
Allopurinol 25mg qdwas added to the therapeutic regimen on
day 1 of the second cycle, if the 6-TGN concentrations were
<350 pmol/8×108 EC and if no relevant toxicity had occurred
(Fig. 1). A subsequent cycle with a higher dose of either
allopurinol or azathioprine according to the dose escalation
scheme (Fig. 1) was started if the two aforementioned criteria
were not met, otherwise, the follow-up month was begun. In
the case of severe toxicity, the combination was stopped and
the patient excluded from the study. A total of seven cycles
and 1 month of follow-up examination was the maximum
scheduled study duration. The study patients received com-
mercially available azathioprine 50 mg film-coated tablets
(Imurek®; Glaxo SmithKline, Münchenbuchsee, Switzerland,
and ProConcepta Zug, Zug, Switzerland), while allopurinol
25 mg and 50 mg capsules were manufactured by the Can-
tonal Pharmacy of Zürich, Zürich, Switzerland.
The following study procedures were carried out repeated-
ly in each patient: update of medical history, determination of
adverse events, measurement of body temperature and labo-
ratory measurements three times per cycle (on study days 8–
10, 23–25 and 26–28) and a short physical examination.
Crohn's Disease Activity Index (CDAI)/Rachmilewitz disease
activity scores were evaluated to assess clinical response.
Repeated laboratory measurements consisted of a complete
blood cell count, creatinine, lactate dehydrogenase, AST,
ALT, alkaline phosphatase, gamma-glutamyltransferase, total
bilirubin, C-reactive protein and concentrations of the
thiopurine metabolites 6-TGN and 6-MMPN in serum and
blood, respectively. The TPMT activity was measured at
screening and once every month thereafter because the effect
of allopurinol on TPMTactivity was not known at the time of
study design. At the end of each cycle, the allopurinol dose
was adapted according to tolerability, clinical response, hema-
tology and clinical chemistry parameters and 6-TGN
concentrations.
The dose-escalation was finished in an individual patient
when 6-TGN concentrations were ≥350 pmol/8×108 EC or if
moderate/serious toxicity occurred (Fig. 1). The study ended
for each patient after 1 month of follow-up with an end-of
study examination that consisted of laboratory measurements,
physical examination, 12-lead ECG and CDAI/Rachmilewitz
index assessment.
For the patients who were treated with the azathioprine–
allopurinol combination in the context of an individualized
therapeutic approach, dose increments were approximated
to the study protocol. The azathioprine dose was initially
reduced to 50 mg qd for 2–3 weeks, following which an
allopurinol dose of 50 mg qd was added. Further monthly
allopurinol dose increases in steps of 25 mg were intended
in case of persisting subtherapeutic 6-TGN concentrations.
Determination of adverse effects and metabolite and other
laboratory measurements were performed twice each month,
and physical examinations were performed at least once
each month. The patients took in commercially available
azathioprine film-coated tablets (Imurek®) and commercial-
ly available allopurinol tablets (either Mephanol® 100 mg,
Mepha Pharma, Aesch BL, Switzerland, or Allopur®
100 mg, Sandoz, Cham, Switzerland), and each patient
was responsible for dividing the tablets into the proper dose.
The study was approved by the Ethics Committee of the
Canton of Zurich, Switzerland and by the Swiss Health Au-
thority Swissmedic, Bern, Switzerland. It has been registered
at ClinicalTrials.gov with the number NCT00849368.
Metabolite measurements
The cycle duration of 28 days was chosen to ensure that
metabolite concentrations reflected steady state before a
dose increase was performed, as the average half-life of 6-
TGN in EC is 5 days [17–19].
Blood samples for the measurement of 6-TGN and 6-
MMPN concentrations were collected at least 5 h after the
daily drug intake. Blood was collected in vacutainers
supplemented with heparin (5 ml per sample), then spiked
with 100 μl of the antioxidant 1,4-dithio-D,L-threitol at a
concentration of 1 mg/ml and stored at −20 °C until analy-
sis. 6-TGN and 6-MMPN were measured using a validated,
specific and selective high-performance liquid chromatog-
raphy (HPLC) method [20, 21]. The HPLC system consisted
of a 9010 pump, a ProStar 410 autosampler and a 9050 UV-
VIS detector (Varian, Sunnyvale, CA). The lower limit of
quantification (LLQ) was 50 pmol/8×108 EC for TGN
and 100 pmol/8×108 EC for MMPN. For values under
the LLQ, one-half of the LLQ was considered for further
analysis.
TPMT activity
The TPMT assay (5 ml EDTAwhole blood) was performed
according to Kröplin et al. [22] with minor modifications.
The Hb of the red blood cell lysate was measured by a
Microcell counter F500 (Sysmex, Hamburg, Germany).
The sample volume of each patient consisted of 50 μl red
blood cell lysate (in accordance with the published method),
whereas the extraction of the product was made with
dichlormethane/2-propanol (90/10; v/v). The same HPLC
system as for metabolite quantifications was used. The cut-
off between normal and intermediate or low TPMT activity
was defined as 30 nmol MTG/gHb/h.
Statistical analysis
Descriptive analyses were performed in all 12 patients. The
results are presented as median values and ranges.
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Results
Study patients
The baseline characteristics of the study patients are presented
in Table 1.
At inclusion, five of six patients had 6-TGN concentrations
below the recommended threshold of 235 pmol/8×108EC
(Fig. 2a) and five of six patients showed elevated MMPN
concentrations of >5,000 pmol/8×108 EC (Fig. 3a). One of
these patients initially had normal 6-TGN. Four patients need-
ed corticosteroids at study entry. Three patients had mildly
elevated liver transaminases up to threefold the ULN (all
considered to be azathioprine-related), one had an additional
total bilirubin elevation (1.5-fold ULN). With the exception of
slightly reduced neutrophil counts in one patient (1,220/μl,
normal range 1,400–8,000/μl) and reduced lymphocyte
counts in three patients (270–970/μl, normal range 1,500–
4,000/μl), all other laboratory values, including markers of
inflammation, were normal.
In one of the two patients with CD, the CDAI of 162
points revealed clinically active disease (active disease >150
points). The other CD patient (CDAI 40 points) and all four
patients with UC were in clinical remission (Rachmilewitz
index <4 points).
Five of six patients completed the study. One patient
achieved therapeutic 6-TGN concentrations with a combina-
tion of allopurinol 25 mg qd and azathioprine 50 mg qd,
whereas four patients needed allopurinol 50 mg qd in combi-
nation with azathioprine 50 mg qd (Fig. 2a). One CD patient
dropped out due to nausea at the azathioprine 50 mg dose
level. The median 6-TGN and MMPN concentrations, TPMT
activity, leukocyte and lymphocyte counts and ALT, AST and
bilirubin values at the different azathioprine and allopurinol
dose levels are shown in Table 2. In all five patients who
completed the study, MMPN concentrations normalized dur-
ing the first 8–10 days after the reduction of azathioprine to
50 mg qd (first cycle) and remained normal after the addition
of allopurinol to the therapeutic regimen (Fig. 3a). In both
patients with initially elevated liver enzymes who completed
the study, liver enzymes normalized at the azathioprine 50 mg
qd dose level and remained stable thereafter. One patient with
initially normal liver enzymes developed elevated transami-
nases up to 5.7-fold greater than the ULN in the course, which
normalized at follow-up without any modification of the doses
of azathioprine and allopurinol. At the end of the study labo-
ratory examinations revealed normal liver enzyme levels in all
patients. Lymphocytes were below the lower limit of normal
range in three patients 1,190–1,300/μl at the end of the follow-
up. Routine laboratory testing found no relevant abnormalities
in any patient at the end of the study.
The CDAI values and the Rachmilewitz indices were be-
low 150 and 3, respectively, throughout the study in four
patients. The administration of corticosteroids was stopped
in three patients after the addition of allopurinol. One UC
patient with azathioprine and rectal corticosteroids at study
Fig. 1 Study dose escalation scheme. Asterisk If 6-thioguanine nucle-
otide (6-TGN) concentrations were <350 pmol/8×108erythrocytes
(EC) and there were no signs of major or minor toxicity, the next dose
increment was initiated. Serious toxicity was defined as: neutrophils
<500/μl and/or hemoglobulin (Hb) decline of >2 g/dl and/or thrombo-
cytes <100,000/μl and/or lymphocytes <500/μl and/or rise in alanine/
aspartate aminotransferases (ALT/AST) of >50 % of the pre-study
examination value and/or diagnosis of pancreatitis independent of 6-
TGN concentrations. Moderate toxicity was defined as: neutrophils
1,000–1,500/μl, Hb decline of <2 g/dl, thrombocytes 100,000–
140,000/μl, ALT/AST rise of 15–50 % of the pre-study examination.
In case of moderate toxicity: maintenance of dose level, in case of
persistence for >1 month: study termination
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entry, who was in remission based on clinical and endoscopic
evidence, relapsed at the azathioprine 50 mg dose level (first
cycle) and exhibited an intermittent liver enzyme increase.
The therapeutic regimen of this patient was supplemented
with oral prednisone until the follow-up period. The
Rachmilewitz indices in this patient were 3, 11, 1, 4, 4 and 0.
At the end of the study all patients were clinically in
remission and were receiving neither oral nor rectal
corticosteroids. With the exception of the above-mentioned
transient liver enzyme increase, all patients who finished the
study tolerated the azathioprine–allopurinol combination
without relevant signs of toxicity.
TPMT activity
Thiopurine methyl transferase activity was normal in all
patients at study entry and did not change after the addition
of allopurinol to the therapeutic regimen (Table 2).
Non-study patients
The baseline characteristics of the five IBD patients
who were treated with azathioprine and allopurinol in
the context of an individualized therapeutic approach are
presented in Table 3. Concomitant diseases precluding
study inclusion were a chronic depression, bronchial
asthma, obesity (BMI 35 kg/m2), hypertensive and cor-
onary heart disease and primary sclerosing cholangitis.
At the time of allopurinol initiation, two patients were
receiving oral corticosteroids. All patients had
subtherapeutic 6-TGN concentrations ranging from 71
to 234 pmol/8×108 EC (Fig. 2b) and three had elevated
MMPN concentrations of >5,000 pmol/8×108 EC
(Fig. 3b). The median 6-TGN and MMPN concentra-
tions, leukocyte and lymphocyte counts and ALT, AST
and bilirubin values at the different azathioprine and
allopurinol dose levels are shown in Table 4. All pa-
tients had active disease based on clinical and/or endo-
scopic evidence despite adequate azathioprine dosing of
2–2.5 mg/kg body weight and adequate therapy dura-
tion. In one CD patient infliximab as an add-on therapy
to oral budesonide and azathioprine was stopped 5
months before initiation of the azathioprine–allopurinol
combination therapy due to intolerable pruritus and er-
ythema. Following discontinuation of infliximab the pa-
tient suffered from clinically active disease despite
therapy with 9 mg oral budesonide qd in combination
with azathioprine. The other CD patient had persistent
abdominal pain and elevated calprotectin levels in the
feces. One UC patient had recurrent bloody diarrhoea,
persistently elevated calprotectin values in the feces and
chronic iron deficiency, all of which are indicators of
chronic active disease. One UC patient with pancolitis
showed low 6-TGN concentrations and chronic active
disease based on endoscopic findings. This patient re-
fused tumor necrosis factor (TNF) blocker therapy. The
third patient with UC had endoscopically confirmed
moderate left-sided colitis and needed oral prednisone
repeatedly.
All patients had normal TPMT activities in the beginning
and during the dose-escalation procedure. Total bilirubin was
Table 1 Baseline characteristics of the study patients
Baseline characteristics Valuesa (range)
Median age (years) 40.5 (23–47)
Gender (female/male) (n) 6 / 0
Diagnosis (n)
Crohn’s disease 2
Ulcerative colitis 4
Median disease duration
(years)
4.5 (0.5–20)
Crohn’s disease activity index
(CDAI)
40–162
Rachmilewitz Index for ulcerative
colitis
1–3
Median body mass index
(kg/m2)
24.7 (20.4–37.5)
Concomitant medications (n)
ASA 3
Calcium 5
Vitamin D3 6
Corticosteroids (oral) 2
Corticosteroids (rectal) 3
Median AZAa dose prior to study
entry (mg/day)
150 (125–200)
Median AZAa dose prior to study
entry (mg/kg bw/day)
2.2 (2.0–2.9)
Median 6-TGN concentrations
(pmol/8×108EC)
208 (106–270)
Median MMPN concentrations
(pmol/8×108EC)
7,678.5 (2,351–16,928)
Median TPMT activity
(nmol MTG/gHb/h)
44.5 (34–57)
Median leukocytes (/μl) 6,680 (2,390–8,120)
Median lymphocytes (/μl) 1,240 (270–2,400)
Median total bilirubin (μmol/l) 10 (8–31)
Median ALT (U/l) 35.5 (15–105)
Median AST (U/l) 29.5 (21–45)
ASA, 5-aminosalicylic acid; AZA, azathioprine; bw, body weight; 6-
TGN, 6-thioguanine nucleotide; MMPN, methylmercaptopurine nucle-
otide; TPMT, thiopurine methyl transferase; ALT/AST alanine/aspar-
tate aminotransferase
a Normal ranges: Leukocytes, 3,000–9,600 /μl;
lymphocytes, 1,500–4,000 /μl; bilirubin, <21 μmol/l; ALT, 10–35 U/l
(female)/10–50 U/l (male); AST, <35 U/l (female)/<50 U/l (male)
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elevated in one patient with UC who had a genotypically
confirmed Gilbert’s syndrome [homozygous mutation in the
UGT1A1 promoter, genotype (TA)7/(TA)7]. The other four
patients had normal liver enzymes. Routine laboratory
examinations detected no pathological findings with the
exception of moderate lymphopenia in four patients
(750–1,250/μl, normal range 1,500–4,000/μl), mild ane-
mia in two patients (12.6 g/dl, normal range 13.4–
17.0 g/dl), mild leukopenia in one patient (2,850/μl,
normal range 3,000–9,600/μl) and elevated C-reactive
protein in one patient (6.3 mg/l, reference <5 mg/l).
All patients achieved stable therapeutic 6-TGN concen-
trations with azathioprine 50 mg qd and allopurinol 50 mg
qd (Fig. 2b). In all patients MMPN concentrations dropped
to normal values ranging between 228 and 1,581 pmol/8×
108 EC after the azathioprine dose had been reduced to
50 mg qd. MMPN concentrations remained low or dropped
further in all patients during dose-escalation and follow-up
(Fig. 3b). Liver enzymes remained normal in all patients. At
the end of the follow-up no patient had leukopenia or
neutropenia. Except for stable lymphopenia, other signifi-
cant laboratory abnormalities were not observed.
Fig. 2 Individual 6-TGN
concentration vs. time courses
in five patients participating in
the dose-finding study (a) and
in five patients who received
the combination outside the
study (b). a Patients received
50 mg azathioprine daily
(median 0.7 mg/kg, range 0.6–
0.9 mg/kg) as monotherapy for
28 days before the combination
was started. Dotted lines
Therapeutic ranges, dashed line
study target concentration. b
Patients received 50 mg
azathioprine daily (median
0.7 mg/kg, range 0.5–1.0 mg/
kg) as monotherapy for 2–
3 weeks, before the
combination therapy was
started. Dotted line Minimal
recommended 6-TGN
concentration [235 pmol/8×108
erythrocytes (EC)]
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At the end of the follow-up, all three non-study UC
patients were in remission (two patients clinically and
the patient with initially chronic-active pancolitis, both
clinically and endoscopically). One CD patient was
clinically in remission with intake of a reduced
budesonide dose. One CD patient improved clinically, but
still had very mild ileitis based on endoscopic evidence.
Corticosteroid treatment had ceased in one of two patients
with initial intake and had tapered in the other one. The
allopurinol–azathioprine combination therapy was well toler-
ated by all patients.
Long-term follow up
Although the scheduled follow-up according to the protocol
was only 1 month, we can report a much longer follow-up
for several patients. After 3 years of combination therapy,
one non-study UC patient and one study CD patient are still
in remission without signs of toxicity. After 1 year of ther-
apy, one UC patient is in remission based on clinical and
endoscopic findings. Another UC patient relapsed 6 months
after study completion and finally required TNF-alpha
blocker therapy. The follow-up for the other study and non-
Fig. 3 Individual
methylmercaptopurine
nucleotide (MMPN)
concentration vs. time courses
in five patients participating in
the dose-finding study (a) and
in five patients who received
the combination outside the
study (b). a Patients received
50 mg azathioprine daily as
monotherapy for 28 days,
before the combination was
started. b Patients received
50 mg azathioprine daily as
monotherapy for 2–3 weeks,
before the combination was
started. Dotted line Upper limit
of normal MMPN
concentrations (5,000 pmol/8×
108 EC)
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study patients was 6–9 months. One patient had an acute
relapse that was successfully treated with rectal corticoste-
roids, and another patient still has mildly active disease. The
other four patients have remained in remission, in two of these
clinical remission was confirmed endoscopically.Ta
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Table 3 Baseline characteristics of the non-study patients
Baseline characteristics Values (range)
Median age (years) 35 (20–68)
Gender (female/male) (n) 2/3
Diagnosis (n)
Crohn’s disease 2
Ulcerative colitis 3
Median disease duration (years) 9 (2–15)
Median body mass index (kg/m2) 24.8 (17.9–35.0)
Concomitant medications (n)
ASA 3
Calcium 1
Vitamin D3 1
Corticosteroids (oral) 1
Corticosteroid s(rectal) 3
Antihypertensives 1
Statins 1
Thyroid hormone 1
Antiplatelets 1
Antidiarrheals 2
Spasmolytic drugs/analgesics 2
Antipsychotics 1
Benzodiazepines 1
Antiasthmatics 1
Colestyramine 1
Other vitamins 1
Median AZA dose prior to study entry
(mg/day)
150 (100–250)
Median AZA dose prior to study entry
(mg/kg bw/day)
2.2 (1.8–2.3)
Median 6-TGN concentrations
(pmol/8×108EC)
151 (71–234)
Median MMPN concentration
(pmol/8×108EC)
6,086 (2,794–13,783)
Median TPMT activity
(nmol MTG/gHb/h)a
52.5 (44–56)
Median leukocytes (/μl) 7,250 (2,850–8,910)
Median lymphocytes (/μl) 1,150 (750–2,040)
Median total bilirubin (μmol/l)b 7 (3–25)
Median ALT (U/l) 24 (12–50)
Median AST (U/l) 30 (22–34)
Normal ranges and abbreviations: See footnote to Table 1
a Value of one patient, which was assessed after the addition of allopu-
rinol to the therapeutic regimen, was not included
b The patient with an elevated total bilirubin had confirmed Gilbert’s
syndrome with a homozygous mutation in the UGT1A1 promoter
[UGT1A1 promoter genotype (TA)7/(TA)7]
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Discussion
Our study provides evidence that lower doses than previ-
ously reported of both azathioprine and allopurinol are
sufficient to achieve therapeutic 6-TGN concentrations and
to reverse elevated MMPN concentrations and elevated liver
enzymes in IBD patients with insufficient response to aza-
thioprine monotherapy. In our patients, a maximum dose of
50 mg azathioprine in combination with 50 mg allopurinol
was sufficient to achieve biochemical response. This low-
dose combination was adequate not only in the setting of a
clinical study, but also in patients who did not meet the strict
study inclusion criteria.
The use of thiopurines is limited due to a lack of response
or side effects in approximately one-third of IBD patients [23,
24], and 10–15 % of patients do not achieve therapeutic 6-
TGN concentrations and have preferential MMPN metabo-
lism [1–4]. Several studies have reported the favorable meta-
bolic interaction between thiopurines and allopurinol in IBD
patients—if thiopurine doses are reduced to avoid excessive
bone marrow toxicity. Dosing in these studies was usually
based on recommendations from the literature. Typically,
thiopurine doses were reduced to 25–50 % of the initial
thiopurine dose and combined with allopurinol 100–300 mg
qd [6–9, 12–15]. In one retrospective chart analysis, a starting
dose of allopurinol 50 mg qd in combination with thiopurines
was recommended [25]. Not only hepatotoxicity but also
myelosuppression is one of the most relevant side effects of
thiopurine therapy. In several of the thiopurine–allopurinol
combination trials, leukopenia rates ranged between 20 and
50 % [6, 7, 12, 14]. None of our patients experienced leuko-
penia or neutropenia and, overall, the combination was well
tolerated. In one patient with an acute UC flare after the
azathioprine dose had been reduced to 50 mg qd, transami-
nases increased after the initiation of oral prednisone
treatment; this increase was probably not related to allopurinol
but to prednisone. Considering the overall good tolerability in
our patients, lower dosing might be a helpful means to reduce
toxicity rates.
There are, however, a number of unresolved questions
about azathioprine dose adaptations. In our study, we defined
a target 6-TGN concentration limit of 350 pmol/8×108EC;
this had to be attained to begin with the follow-up period and
to stop dose-escalation. According to the literature, the thera-
peutic range of 6-TGN concentrations is 235–450 pmol/8×
108EC [1, 21, 26]. However, the upper limit of 450 pmol/8×
108EC is not well corroborated by experimental data. As
thiopurine concentrations show a high variability between
two measurements, the target of 350 pmol/8×108EC was
chosen to ensure that the concentrations were reliably within
the therapeutic range when the decision on further dose in-
crease or initiation of the follow-up was made. Additionally,
this value is roughly the mean of the therapeutic range.
The mechanism of how allopurinol increases 6-TGN
concentrations and at the same time lowers MMPN concen-
trations remains to be elucidated. An effect of allopurinol on
TPMT activity could neither be demonstrated in vitro nor in
vivo [6, 7], which is in accordance with our observation that
TPMT activity in the study patients did not change. Further-
more, current data do not support the hypothesis that allo-
purinol metabolites inhibit TPMT activity and thus decrease
MMPN production [7]. Other, so far unproven explanations
might be the induction of other enzymes, such as hypoxan-
thine guanine phosphoribosyltransferase and/or of enzymes
which biotransform MMPNs, or the inhibition of unknown
TPMT co-enzymes by allopurinol or its metabolites. Alter-
natively, the mere reduction of azathioprine dose may inter-
fere with the activation of TPMT and thus lower MMPN
concentrations simply by decreasing the azathioprine bur-
den. To our knowledge, we are the first to perform an
Table 4 Results of the laboratory examinations at the different dose levels in the non-study patients
Laboratory parameter Azathioprine
50 mg/day
Azathioprine 50 mg/day + allopurinol 50 mg/day Maintenance dose azathioprine
50 mg/day + allopurinol 50 mg/day
Week 1–2 Week 1 Week 2 Week 4 Follow-up week 3–4
6-TGN
(pmol/8×108EC)
126 (63–177) 359 (175–482) 389 (243–629) 311 (274–401) 361 (304–458)
MMPN
(pmol/8×108 EC)
497 (228–1,581) 223 (50–958) 342 (50–743) 380 (100–750) 441 (50–1,790)
Leukocytes (/μl) 5,640 (2,720–11,620) 5,900 (3,480–10,570) 6,000 (4,820–8,110)
Lymphocytes (/μl) 1,210 (360–1,990) 1,290 (340–2,350) 1,110 (520–2,350)
Bilirubin total (μmol/l) 7 (3–34) 6 (2–30) 7.5a (2–15)
ALT (U/l) 13 (12–25) 16 (13–29) 17 (12–25)
AST (U/l) 24 (19–30) 22 (19–40) 28 (20–35)
Normal ranges and abbreviations: See footnote to Table 1
Data are presented as the median (n = 5) with the range in parenthesis
a Value for one patient missing
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azathioprine dose-reduction phase prior to combination with
allopurinol. MMPN concentrations were already normalized
in all of our patients after the azathioprine dose had been
reduced to 50 mg qd. Since the median MMPN remained
stable after the addition of allopurinol to the therapeutic
regimen, this observation supports the hypothesis that re-
duction of the azathioprine dose burden is responsible for
the rapid normalization of MMPN concentrations.
Three of five patients who completed the study needed oral
and/or rectal corticosteroids to be in remission at inclusion,
and one patient had active disease despite oral prednisone
intake. All patients had one or more episodes of corticosteroid
intake in the months preceding study entry. Thus, despite
formally normal disease activity indices in most patients at
inclusion, response to thiopurine monotherapy was unsatis-
factory. Likewise, all non-study patients had clinically active
disease prior to the addition of allopurinol to the therapeutic
regimen. In conclusion, the good response to the allopurinol–
azathioprine combination can not be explained simply by a
mild disease activity prior to allopurinol addition.
Up to the present, seven of the ten patients remain in
remission based on clinical and/or endoscopic findings. This
number is in accordance with data from the literature de-
scribing clinical response rates for the thiopurine–allopuri-
nol combination of >70 % [7, 9, 12]. However, our patients
took lower doses to reach the same result. Follow-up periods
of up to 71 months [8] have shown that thiopurines and
allopurinol can be safely and effectively combined for long
time periods.
After study completion metabolite concentrations were
controlled every 3–6 months in our patients. Without any
obvious explanation, in one CU patient, 6-TGN concentra-
tions continued to rise above 500 pmol/8×108EC after ap-
proximately 6 months of combination therapy. This led to
the azathioprine being reduced to an alternating dose of
50 mg and 25 mg qd, while allopurinol was maintained at
50 mg qd. According to the literature, the estimated half-life
of 6-TGN in EC is 3–13 days, with an average of about
5 days [17, 19, 27]. However, much longer half-lives have
been reported [28], and our observation in one patient may
be explained by 6-TGN accumulation caused by prolonged
elimination.
We decided to apply the allopurinol–azathioprine combi-
nation therapy in five patients who did not fulfil the study
inclusion criteria, as all five patients were insufficiently treated
with azathioprine alone. The aim was to avoid a therapy
escalation to a TNF-alpha blocker. With the exception of
xanthine oxidase inhibitors, such as allopurinol, and
aminosalicylates, which inhibit TPMT activity in high doses
[29], no pharmacokinetic drug interactions affecting
thiopurine metabolite concentrations are known for azathio-
prine. Thus, the concomitant medications should not have had
any significant influence on azathioprine pharmacokinetics.
Seven patients had lymphopenia at follow-up, which is a
recognized effect of thiopurines [30]. One of these patients
received corticosteroids at follow-up, which may have con-
tributed to the lymphopenia. In the patient with the lowest
lymphocyte count at inclusion (750/μl), lymphocytes
dropped to as low as 320/μl, but finally reached stable values
of approximately 500/μl at follow-up. Lymphopenia-related
complications, such as infections, did not occur in any of
the patients. Interestingly, two of the patients with normal
lymphocyte counts relapsed.
A shortcoming of our study is the low number of patients.
However, in view of the consistency of the clinical and
biochemical results within and outside the study protocol,
the number of relapses, which is comparable to treatments
with higher doses, and the length of follow-up, it may be
concluded that low doses of 50 mg allopurinol in combina-
tion with 50 mg azathioprine qd are sufficient in most IBD
patients with inadequate thiopurine metabolite concentra-
tions. Even in patients with relevant comorbidities, the
low-dose combination proved to be efficacious and safe.
Tolerability can be optimized and thiopurine-induced toxic-
ity, such as leukopenia, can be prevented by lowering doses
to the required minimum. Further studies are necessary to
confirm our findings in larger patient groups and to evaluate
if the low-dose combination may also prevent toxicity and
improve efficacy in thiopurine-naїve patients.
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